On the other hands, baseline DAS28 for the 20 patients was 4.8±0.3 (2.5-6.8) in TCZ group. There were no differences between ADA and TCZ groups. RA patients with an insufficient response to ADA or TCZ showed highly significant improvement of DAS28 after 12 weeks (2.9±0.3 and 2.2±0.4, respectively), and 24 weeks (2.5±0.4 to 2.2±0.2, respectively). ADAM-10 highly correlates with CDAI, and fractalkine/CX3CL1. Serum ADAM-10 levels were no remarkable change after treatment with ADA despite decrease of disease activity of RA. On the other hand, serum ADAM-10 levels in patients who were treated with TCZ were significantly diminished following successful treatment and clinical improvement (baseline 408±88 pg/ml and 54 weeks 138±51 pg/ml, p<0.05). Univariate logistic regression analysis, baseline of DAS28 (ESR), baseline of CDAI, and ADAM-10 were selected as significant variables for improvement of DAS28 (ESR) at 24 weeks. Multiple regression analysis showed that ADAM-10 was only identified as independent predictive variable for improvement of DAS28 (ESR) at 24 weeks. ADAM-10 baseline in TCZ responder was significantly higher than TCZ nonresponders at 24 weeks (620±134 pg/ml and 109±25 pg/ml, respectively, p<0.05). Conclusions: This study indicates that ADAM-10 is correlated with RA disease activity, and is higher in TCZ responders. These results suggest that ADAM-10 may be a predictor of treatment effectiveness for RA with TCZ. Background: Rheumatoid arthritis (RA), and especially seronegative RA, is often ameliorated by pregnancy, while systemic lupus erythematosus (SLE) is prone to flare and associated with pregnancy complications. Cytokines and chemokines are of great importance for immune processes during pregnancy. The inflammatory marker Lipocalin-2 (LCN2) has become increasingly relevant as a potential clinical biomarker of rheumatic diseases (1). LCN2 is produced in the maternal-fetal interface during normal pregnancies and correlates with the presence and severity of preeclampsia (2). Objectives: To obtain a better understanding of immune regulation and the disparate immune responses in pregnant women with RA and SLE. In this pilot study, we analyzed levels of multiple cytokines, chemokines and LCN2 in women with seropositive RA, seronegative RA, SLE and healthy controls during pregnancy and postpartum. Methods: The Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases collect serum samples in a biobank from women with inflammatory rheumatic diseases before pregnancy, during pregnancy week 10-12, week 23-25, week 30-32 and 6 weeks, 6 months and 12 months postpartum. Control serum samples were collected from healthy pregnant women at matching timepoints. We analyzed serum cytokine and chemokine levels using a multiplex assay. A sandwich ELISA was used to measure LCN2. In this pilot study we included pregnant women with SLE (n=4), seropositive RA (n=4), seronegative RA (n=2) and healthy pregnant controls (n=4). The total cohort consists so far of 18 pregnant women with SLE and 23 pregnant women with RA. Results: We observed lower LCN2 levels during pregnancy in SLE patients, compared to controls and RA patients. LCN2 levels in seropositive RA patients and controls were found to be comparable during pregnancy, whereas pregnant women with seronegative RA showed higher LCN2 levels. Levels of IFNγ, IL-6 and IP-10 were higher in SLE than in RA patients during the course of pregnancy. IL-17 was slightly higher only in seropositive RA patients compared to controls. TNFα was slightly higher in both SLE and RA patients compared to controls, levels of anti-inflammatory IL-10 were very low or undetectable in all groups.
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Trimester
Controls SLE Seropos RA Seroneg RA LCN2 (ng/ml) 285,5 (±74,7) 126,5 (±44,6) 232,6 (±67,4) 330,2 (±3,2) IFNγ (pg/ml) 15,0 (±22,4) 40,4 (±65,1) 6,9 (±5,2) 26,1 (±9,9) IL-6 (pg/ml) 3,4 (±1,9) 5,9 (±2,0) 3,8 (±1,5) 5,3 (±1,0) IP-10 (pg/ml) 60,3 (±14,5) 138,3 (±92,1) 61,7 (±8,9) 64,9 (±7,3) IL-17 (pg/ml) 1,3 (±1,3) 2,3 (±2,2) 4,8 (±9,0) 0,6 (±0,2) TNFα (pg/ml) 2,2 (±2,5) 4,2 (±5,4) 3,3 (±3,5) 3,2 (±0,7)
Conclusions: We found interesting differences in cytokine, chemokine and LCN2 levels during pregnancy in women with SLE, seropositive RA and seronegative RA. The results need confirmation in the total cohort and will be further explored for a better understanding of the disparate immune modulation of RA and SLE during pregnancy. Background: The migration of osteoclast from circulation and bone marrow into bone surface has suggested as a novel therapeutic point for bone erosion in RA. Objectives: We explored the mechanisms involved in osteoclast migration. Methods: Gene expression profiling was identified by microarray analysis and validated by Real-time PCR during differentiation of bone marrow-derived macrophages (BMMs) into osteoclast (OCs). RANKL induced osteoclast precursor cell line RAW264.7 migration and invasion in the presence and absence of anti-CCL4 antibody was measured in vitro. Intracellular signaling pathway was assessed by Western blotting. Osteoclast formation was identified by TRAP staining. Results: A panel of 11 chemokines signal was significant increase in osteoclastic differentiation of BMMs by Microarray. High expression of CCL4 was validated in primary BMMs and RAW264.7 cell line during differentiated into OCs. RANKL induced osteoclast precursor cell migration and invasion was decreased upon addition of anti-CCL4 antibody. OCs formation and OCs related genes expression were not affected by CCL4 inhibition. Neutralization of CCL4 promoted the PI13K phosphorylation at 45 to 60min after RANKL stimulation in RAW264.7. Conclusions: CCL4 regulates RANKL-induced OCs migration, suggesting that CCL4 inhibition could be bone protective in RA References:
[1] Boyce BF: Advances in the regulation of osteoclasts and osteoclast functions.
Journal of dental research 2013, 92(10):860-867. 
